Irinotecan is a chemotherapy drug that is used to treat various types of cancer, including colorectal cancer and lung cancer. In this article, we will discuss irinotecan's chemical formula, health benefits, potential effects, mechanism of action, safety, side effects, dosing information, and conclusion.
Chemical name, Molecular formula, Formula weight, and CAS No:
The chemical name for irinotecan is (4S)-4,11-diethyl-4-hydroxy-9-[(4-phenylbutyrate)oxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione. Its molecular formula is C33H38N4O6, and the formula weight of this drug is 586.68 g/mol. The CAS number for irinotecan is 97682-44-5.
Top ten keywords from Google and Synonyms Synonym:
Synonyms for irinotecan include Camptosar, CPT-11, and SN-38.
Health benefits of irinotecan:
Irinotecan is used to treat various types of cancer, including colorectal cancer and lung cancer. It works by inhibiting an enzyme called topoisomerase, which is needed for DNA replication and cell division. By inhibiting this enzyme, irinotecan can slow down or stop the growth of cancer cells. Irinotecan has been shown to improve overall survival and progression-free survival in patients with colorectal cancer and lung cancer.
Potential effects of irinotecan:
In addition to its antitumor activity, irinotecan has been shown to have other potential effects. It has been shown to increase the production of a protein called nitric oxide synthase, which can help to prevent the growth and spread of cancer. Irinotecan has also been shown to increase the activity of the immune system, which can help to destroy cancer cells.
Product mechanism:
Irinotecan is a topoisomerase inhibitor that works by inhibiting the activity of the enzyme topoisomerase. Topoisomerase is needed for DNA replication and cell division, so by inhibiting this enzyme, irinotecan can slow down or stop the growth of cancer cells. Irinotecan is converted in the body to an active metabolite called SN-38, which is responsible for its antitumor activity.
Safety:
Irinotecan is generally well-tolerated, but it can cause some side effects. The most common side effects of irinotecan include diarrhea, nausea, vomiting, and fatigue. Other side effects can include low blood cell counts, allergic reactions, and secondary cancer. Irinotecan should not be used by patients who have a history of allergic reactions to the drug or its components.
Side effects:
Irinotecan can cause a range of side effects, including diarrhea, nausea, vomiting, and fatigue. It can also cause low blood cell counts, which can increase the risk of infection, bleeding, and anemia. Allergic reactions to irinotecan can include rash, itching, and difficulty breathing. Irinotecan can also increase the risk of secondary cancer, including leukemia. Patients who experience any side effects from irinotecan should contact their healthcare provider immediately.
Dosing information:
Irinotecan is administered via intravenous infusion over a period of 90 minutes. The recommended dose of irinotecan for the treatment of metastatic colorectal cancer is 125 mg/m2, and it is given every two weeks. The recommended dose of irinotecan for the treatment of metastatic lung cancer is 60-100 mg/m2, and it is given every three weeks. The dose of irinotecan may need to be adjusted based on a patient's individual needs and health status.
Conclusion:
Irinotecan is a chemotherapy drug that is used to treat colorectal cancer and lung cancer. With its potent antitumor activity and other potential effects, irinotecan has the potential to improve outcomes for cancer patients. It is important to understand the potential side effects of irinotecan and to work closely with a healthcare provider to develop an appropriate treatment plan. While irinotecan is generally well-tolerated, it is important to monitor for any signs of side effects or adverse reactions.
